DNTH

Dianthus Therapeutics Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Dianthus Therapeutics sales and earnings growth
DNTH Growth
Low
  • Revenue Y/Y↓ -42.64%
  • EPS Y/Y↓ -148.74%
  • FCF Y/Y↓ -74.92%
Dianthus Therapeutics gross and profit margin trends
DNTH Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -4104.80%
  • ROIC↓ -34.90%
Dianthus Therapeutics net debt vs free cash flow
DNTH Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Dianthus Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗